PRKAA2 and hepatocellular carcinoma: The mild inhibitory effect of aldometanib on the proliferation of various HCC cells, possibly through reduced levels of anabolic activities after AMPK activation, also does not account for the reduction in tumor size, as the orthotopic allografts were formed prior to aldometanib administration.